Financials data is unavailable for this security.
View more
Year on year Concord Biotech Ltd grew revenues 19.20% from 8.53bn to 10.17bn while net income improved 28.33% from 2.40bn to 3.08bn.
| Gross margin | 77.16% |
|---|---|
| Net profit margin | 30.18% |
| Operating margin | 37.28% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Concord Biotech Ltd increased its cash reserves by 332.73%, or 116.43m. The company earned 2.65bn from its operations for a Cash Flow Margin of 26.10%. In addition the company used 1.55bn on investing activities and also paid 992.15m in financing cash flows.
| Cash flow per share | 35.07 |
|---|---|
| Price/Cash flow per share | 62.20 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items increased 28.33%.
| Div yield(5 year avg) | 0.12% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 29.23% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 27.64 |
More ▼
